CHMP Recommends Approval for NewAmsterdam Pharma’s Obicetrapib for Cholesterol

Key Facts

In a move reflecting advancements in the European biotech sector, NewAmsterdam Pharma and Menarini Group received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. The committee recommended marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (a fixed-dose combination with ezetimibe). This recommendation is based on clinical data demonstrating the efficacy of obicetrapib in lowering LDL cholesterol, moving the drug closer to final approval by the European Commission.

According to reports, this positive CHMP opinion serves as a major regulatory milestone, significantly increasing the probability of commercialization within the EU market. The treatments target cardiovascular conditions, including primary hypercholesterolemia and mixed dyslipidemia. This development comes as the company navigates the final stages of regulatory review, though actual results may vary based on the European Commission's final decision and the firm's ability to execute its commercial milestones.

On the broader economic front, per market data, the Eurozone Economic Sentiment was reported at 23.4 on July 21, 2026, which may influence the general investment climate for pharmaceutical entities operating in the region as they await further regulatory catalysts.